N/A
Completed N=1,216
Pharmacy Delivery to Expand the Reach of PrEP in Kenya
Source: ClinicalTrials.gov NCT04558554 ↗Enrolled (actual)
1,216
Serious AEs
0.0%
Results posted
Mar 2024
Primary outcomePrimary: PrEP Initiation — 287; 661 Participants
Summary
3 consecutive studies to test a novel model for PrEP initiation and refills in Kenya: pharmacy-based PrEP delivery.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY PrEP Initiation |
287; 661 | — |
| PRIMARY PrEP Retention |
153; 41; 476; 134; 65; 185 | — |
| SECONDARY PEP Initiation |
162 | — |
| SECONDARY Selection of Pharmacy-based PrEP Refills |
3 | — |
| SECONDARY PrEP Adherence |
16; 16 | — |
| SECONDARY STI Testing Uptake |
53 | — |
| SECONDARY Transition From PEP to PrEP |
30 | — |
| SECONDARY PrEP Initiation Among STI Testing Clients |
45 | — |
| SECONDARY Selection of Option to Self-administer HIV Risk Assessment Screening Tool |
151 | — |
Eligibility Criteria
Inclusion Criteria
- >=18 years
- Interested in initiating PrEP at a pilot pharmacy (Study 1a and Study 2), interested in refilling PrEP at a pilot pharmacy (Study 1b), or interested in initiating PEP and/or STI testing at a pilot pharmacy (select pharmacies in Study 2 only)
- Initiated PrEP at a project-affiliated clinic (Study 1b only)
- Meets all criteria (e.g., tests HIV-negative) on checklist for initiating and/or refilling PrEP (all phases), PEP (Study 2 only), and/or STI testing (Study 2 only)
- Able & willing to provide written informed consent
Exclusion Criteria
- Currently pregnant or breastfeeding (Study 1a & 1b only)
Data sourced from ClinicalTrials.gov (NCT04558554). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.